,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2015-07-18 22:05:00,Research and development is an important metric to consider when looking for consumer goods stocks that will outperform the market for many years to come.,0.32391098141670227,0.009223124012351036,0.6668659448623657,neutral,0.3146878480911255
1,2015-07-18 22:05:00,"Not only does research and development give companies a competitive edge against rivals, but it also helps them pioneer new product categories that in turn fuel revenue growth.",0.8993160724639893,0.014708531089127064,0.08597540855407715,positive,0.8846075534820557
2,2015-07-18 22:05:00,Analysts are torn on whether R&D spending should be classified on the income statement as an investment or as an expense.,0.0162472166121006,0.17464579641819,0.8091069459915161,neutral,-0.1583985835313797
3,2015-07-18 22:05:00,"However, the important thing for investors is to find companies that strike a balance between rewarding shareholders through dividends and share buybacks, while also investing aggressively in product development and R&D.",0.6519706845283508,0.011271103285253048,0.3367582857608795,positive,0.640699565410614
4,2015-07-18 22:05:00,Enter Johnson & Johnson .,0.060300394892692566,0.018589429557323456,0.921110212802887,neutral,0.04171096533536911
5,2015-07-18 22:05:00,"In fiscal 2014, Johnson & Johnson spent an eye-popping $8.5 billion on research and development -- an increase of 3.8% from the prior year.",0.9505844116210938,0.019633973017334938,0.029781540855765343,positive,0.9309504628181458
6,2015-07-18 22:05:00,"That translates into more than four times what its closest consumer products competitor, Procter & Gamble , spent over the same period.",0.47821319103240967,0.018196024000644684,0.5035908222198486,neutral,0.4600171744823456
7,2015-07-18 22:05:00,"However, one critical distinction between J&J and Procter & Gamble is that in addition to its consumer goods business, Johnson & Johnson also has a robust healthcare and pharmaceutical business.",0.6989829540252686,0.013813619501888752,0.28720349073410034,positive,0.6851693391799927
8,2015-07-18 22:05:00,"This is why, even as an iconic consumer products company with brand names like Band-Aid, Neutrogena, Aveeno, Rogaine, Listerine, Bengay, Tylenol, Benadryl, Nicorette, Pepcid, Motrin, Splenda, Lactaid, and Visine, J&J must spend nearly four times as much on R&D as its closest consumer goods rivals.",0.35759538412094116,0.055612824857234955,0.5867918133735657,neutral,0.3019825518131256
9,2015-07-18 22:05:00,"Last year, Johnson & Johnson spent more than 11% of total sales on R&D.",0.045761629939079285,0.010572567582130432,0.9436658620834351,neutral,0.03518906235694885
10,2015-07-18 22:05:00,"The bulk of that went to the pharmaceutical business, with R&D spending totaling 19.2% of segment sales.",0.018740367144346237,0.01795884221792221,0.9633007645606995,neutral,0.0007815249264240265
11,2015-07-18 22:05:00,"Meanwhile, R&D spending totaled 6.0% of sales for the medical devices segment and 4.3% of sales for the consumer products business.",0.039910949766635895,0.034385863691568375,0.925703227519989,neutral,0.00552508607506752
12,2015-07-18 22:05:00,"Nevertheless, Johnson & Johnson continues to focus meaningful R&D resources on its consumer business as well as its healthcare and medical device segments today.",0.5989736318588257,0.010939566418528557,0.390086829662323,positive,0.5880340933799744
13,2015-07-18 22:05:00,"Last year, the company launched several new consumer and over-the-counter products including women's Rogaine, various new formulas of Listerine, and relaunched innovative versions of key brands like Tylenol PM.",0.4974184036254883,0.009447014890611172,0.49313461780548096,positive,0.48797139525413513
14,2015-07-18 22:05:00,"""Our insight-driven innovation in the consumer business is focused on addressing key consumer need states, led by our 12 megabrands, with 20 new product launches planned for 2015,"" said chief executive Alex Gorsky.",0.6803375482559204,0.010703456588089466,0.30895906686782837,positive,0.6696341037750244
15,2015-07-18 22:05:00,"Thanks to its constant innovation, Johnson & Johnson has been creating superior shareholder returns for over 129 years.",0.9502832293510437,0.01857691816985607,0.031139886006712914,positive,0.9317063093185425
16,2015-07-18 22:05:00,"Moreover, the company's strategy of pouring loads of cash into its R&D efforts is still paying off nicely for Johnson & Johnson.",0.942107081413269,0.01900697499513626,0.038885947316884995,positive,0.9231001138687134
17,2015-07-18 22:05:00,"In fact, new products that the company rolled out within the past five years accounted for as much as 25% of J&J's sales last year.",0.07979180663824081,0.008527888916432858,0.911680281162262,neutral,0.07126391679048538
18,2015-07-18 22:05:00,J&J is also spreading its R&D spending equally across its various businesses.,0.5433453917503357,0.012044760398566723,0.4446098506450653,positive,0.5313006043434143
19,2015-07-18 22:05:00,"In fiscal 2014, for example, no single project represented more than 5% of the total annual budget for research and development.",0.015561236999928951,0.02379612810909748,0.9606426358222961,neutral,-0.00823489110916853
20,2015-07-18 22:05:00,"With a balance sheet that boasts $33 billion in cash and cash equivalents, J&J's cash stash should be able to support both its annual dividend of $2.76 per share, as well as continued R&D spending in the quarters ahead.",0.9404692053794861,0.017222795635461807,0.04230811819434166,positive,0.9232463836669922
21,2015-07-18 22:05:00,The conglomerate's rich history of dividends and buybacks also tells us that the company isn't sacrificing shareholder returns to boost its R&D spending.,0.8295360803604126,0.019175706431269646,0.15128816664218903,positive,0.8103603720664978
22,2015-07-18 22:05:00,"In addition to paying a dividend every year for the past 71 years, the company has also increased its dividend for the last 52 years without fail -- earning it the coveted title of dividend aristocrat.",0.9229686260223389,0.01628408581018448,0.060747236013412476,positive,0.9066845178604126
23,2015-07-18 22:05:00,"The stock's payout ratio of 38% is another positive because it tells investors that for every dollar the company earns in net income, 38% is being returned to shareholders as a dividend.",0.6856894493103027,0.015552111901342869,0.29875847697257996,positive,0.670137345790863
24,2015-07-18 22:05:00,That is both reliable and rewarding at its current level.,0.8651881217956543,0.016732187941670418,0.1180797666311264,positive,0.8484559059143066
25,2015-07-18 22:05:00,"Not only is Johnson & Johnson committed to shareholder returns through dividends, but it also stands tall as a growth stock today thanks to its focus on innovation and industry-leading R&D initiatives.",0.9311092495918274,0.015120191499590874,0.05377056077122688,positive,0.9159890413284302
26,2015-07-18 22:05:00,"With strong cash generation to back it up, investors can expect J&J to be a market leader for many more years to come.",0.931246817111969,0.01471417210996151,0.05403907224535942,positive,0.9165326356887817
27,2015-07-18 22:05:00,"The Motley Fool's mission is to help the world invest, better.",0.6313591599464417,0.013321365229785442,0.3553194999694824,positive,0.6180378198623657
28,2015-07-18 22:05:00,We have done this over the past 20 years by thinking long term and outside the box -- even if that means turning Wall Street on its head.,0.12132513523101807,0.009310020133852959,0.8693649172782898,neutral,0.11201511323451996
29,2015-07-18 22:05:00,"To learn more about what The Motley Fool thinks about current investment trends, and receive a special free report about what might be the next big industry to come out of Silicon Valley, just click here now .",0.04210572689771652,0.012670929543673992,0.9452233910560608,neutral,0.029434796422719955
30,2015-07-18 22:05:00,The article You Won't Believe Which Consumer Products Company Spends the Most on Research & Development originally appeared on Fool.com.,0.01823951117694378,0.008895201608538628,0.9728652834892273,neutral,0.009344309568405151
31,2015-07-18 22:05:00,Tamara Rutter has no position in any stocks mentioned.,0.008521073497831821,0.035248953849077225,0.9562299847602844,neutral,-0.026727881282567978
32,2015-07-18 22:05:00,The Motley Fool recommends Johnson & Johnson and Procter & Gamble.,0.026330091059207916,0.02261643297970295,0.9510534405708313,neutral,0.0037136580795049667
33,2015-07-18 22:05:00,Try any of our Foolish newsletter services free for 30 days .,0.02325451746582985,0.013860778883099556,0.9628846645355225,neutral,0.009393738582730293
34,2015-07-18 22:05:00,"We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.",0.7942618727684021,0.015105843544006348,0.19063223898410797,positive,0.7791560292243958
35,2015-07-18 22:05:00,The Motley Fool has a disclosure policy .,0.016547108069062233,0.01730392687022686,0.9661489725112915,neutral,-0.0007568188011646271
36,2015-07-18 22:05:00,"Copyright Â© 1995 - 2015 The Motley Fool, LLC.",0.02793366275727749,0.023041872307658195,0.949024498462677,neutral,0.004891790449619293
37,2015-07-18 22:05:00,All rights reserved.,0.01556148286908865,0.01622452400624752,0.9682139754295349,neutral,-0.0006630411371588707
38,2015-07-18 22:05:00,The Motley Fool has a disclosure policy .,0.016547108069062233,0.01730392687022686,0.9661489725112915,neutral,-0.0007568188011646271
39,2015-07-18 22:05:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204561054706573,0.01563790813088417,0.9741575717926025,neutral,-0.005433347076177597
